CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell TrialNirali N. Shah, Terry J. Fry, Leah Hoffman et al.|Journal of Clinical Oncology|2020Cited by 422
Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cellsDaniel A. Lichtenstein, Nirali N. Shah, Fiorella Schischlik et al.|Blood|2021Cited by 194
Enhanced clinical-scale manufacturing of TCR transduced T-cells using closed culture system modulesJianjian Jin, Steven L. Highfill|Journal of Translational Medicine|2018Cited by 54
Abstract LB-146: Phase I CD22 CAR T-cell trial updatesNirali N. Shah, Terry J. Fry, Haneen Shalabi et al.|Cancer Research|2019Cited by 4
Abstract LB-146: Phase I CD22 CAR T-cell trial updatesNirali N. Shah, Terry J. Fry, Haneen Shalabi et al.|Clinical Research (Excluding Clinical Trials)|2019Cited by 1